Statins and the risk of pancreatic cancer: A systematic review and meta-analysis of 2,797,186 patients.

Cardiology journal Pub Date : 2024-01-01 Epub Date: 2022-04-04 DOI:10.5603/CJ.a2022.0014

Eryka Karbowska, Damian Swieczkowski, Aleksandra Gasecka, Michal Pruc, Kamil Safiejko, Jerzy R Ladny, Tomasz Kopiec, Milosz J Jaguszewski, Krzysztof J Filipiak, Zubaid Rafique, Lukasz Szarpak

{"title":"Statins and the risk of pancreatic cancer: A systematic review and meta-analysis of 2,797,186 patients.","authors":"Eryka Karbowska, Damian Swieczkowski, Aleksandra Gasecka, Michal Pruc, Kamil Safiejko, Jerzy R Ladny, Tomasz Kopiec, Milosz J Jaguszewski, Krzysztof J Filipiak, Zubaid Rafique, Lukasz Szarpak","doi":"10.5603/CJ.a2022.0014","DOIUrl":null,"url":null,"abstract":"Background: Statin use in many studies is related to the improvement of a patients' condition including reducing the risk of various malignancies. Herein, is a systematic review and meta-analysis to examine the evidence on the association between statin therapy and the risk of the occurrence of pancreatic cancer, mainly in terms of decreased risk of developing pancreatic cancer among patients using statin therapy in the long-term perspective.Methods: PubMed, Web of Science, Scopus and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from database inception to December 1st, 2021. Random effect models were used to estimate summary odds ratios (OR) and the corresponding 95% confidence intervals (CI).Results: A total of 26 studies comprising 2,797,186 patients were included. Polled analysis showed that pancreatic cancer occurrence in statin vs. no-statin group varied and amounted to 0.4% vs. 0.6% (RR = 0.83; 95% CI: 0.72-0.96; I² = 84%; p = 0.01).Conclusions: In summary, the present analysis shows that overall statins use is significantly associated with a reduction in risk of pancreatic cancer. However, these results were not confirmed for the randomized controlled trial subgroup. Further prospective studies are needed to confirm the current results.","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11076033/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiology journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/CJ.a2022.0014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/4/4 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Statin use in many studies is related to the improvement of a patients' condition including reducing the risk of various malignancies. Herein, is a systematic review and meta-analysis to examine the evidence on the association between statin therapy and the risk of the occurrence of pancreatic cancer, mainly in terms of decreased risk of developing pancreatic cancer among patients using statin therapy in the long-term perspective.

Methods: PubMed, Web of Science, Scopus and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from database inception to December 1st, 2021. Random effect models were used to estimate summary odds ratios (OR) and the corresponding 95% confidence intervals (CI).

Results: A total of 26 studies comprising 2,797,186 patients were included. Polled analysis showed that pancreatic cancer occurrence in statin vs. no-statin group varied and amounted to 0.4% vs. 0.6% (RR = 0.83; 95% CI: 0.72-0.96; I² = 84%; p = 0.01).

Conclusions: In summary, the present analysis shows that overall statins use is significantly associated with a reduction in risk of pancreatic cancer. However, these results were not confirmed for the randomized controlled trial subgroup. Further prospective studies are needed to confirm the current results.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

他汀类药物与胰腺癌风险:一项对2,797,186例患者的系统回顾和荟萃分析。

背景:在许多研究中，他汀类药物的使用与患者病情的改善有关，包括降低各种恶性肿瘤的风险。本文通过系统综述和荟萃分析，研究他汀类药物治疗与胰腺癌发生风险之间相关性的证据，主要是从长期角度来看，他汀类药物治疗可降低患者患胰腺癌的风险。方法检索spubmed、Web of Science、Scopus和Cochrane Central Register of Controlled Trials (Central)数据库自建库至2021年12月1日的数据。随机效应模型用于估计总优势比(OR)和相应的95%置信区间(CI)。结果共纳入26项研究，2,797,186例患者。调查分析显示，他汀类药物组和非他汀类药物组的胰腺癌发生率有所不同，分别为0.4%和0.6% (RR = 0.83;95% ci: 0.72-0.96;I²= 84%;P = 0.01)。综上所述，目前的分析表明，他汀类药物的总体使用与胰腺癌风险的降低显著相关。然而，这些结果在随机对照试验亚组中没有得到证实。需要进一步的前瞻性研究来证实目前的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cardiology journal

自引率

0.00%

发文量